SCHEMBL22983352

SCHEMBL22983352

CCOC(=O)c1cccc(NC(=O)c2cccnc2)c1

nearest known ligand 0.84

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.84
MAPT P10636 3/20 0.84
SMN1; SMN2 Q16637 5/20 0.74
RAB9A P51151 6/20 0.73
NPC1 O15118 4/20 0.73
HPGD P15428 1/20 0.73
KDM4E B2RXH2 1/20 0.68
TSHR P16473 2/20 0.64
KCNK3 O14649 1/20 0.64
LMNA P02545 1/20 0.63
MAPK1 P28482 1/20 0.63
TP53 P04637 1/20 0.63
KMT2A Q03164 3/20 0.62
POLB P06746 1/20 0.62
PKM P14618 1/20 0.62
CYP1A2 P05177 1/20 0.62
CYP2C9 P11712 1/20 0.62
MEN1 O00255 2/20 0.60
HTT P42858 2/20 0.60
ABCB1 P08183 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7336785 0.87 ALDH1A1 (0.79) ALDH1A1MAPTSMN1; SMN2RAB9ANPC1
SCHEMBL6793571 0.84 RAB9A (0.76) ALDH1A1MAPTSMN1; SMN2RAB9ANPC1
SCHEMBL24933360 0.83 RAB9A (0.73) ALDH1A1MAPTSMN1; SMN2RAB9ANPC1
SCHEMBL6174341 0.82 TSHR (0.75) ALDH1A1MAPTSMN1; SMN2KDM4ETSHR
SCHEMBL12135284 0.82 ALDH1A1 (0.60) ALDH1A1MAPTSMN1; SMN2RAB9ANPC1
SCHEMBL259177 0.81 TDP1 (0.78) ALDH1A1SMN1; SMN2RAB9ANPC1TSHR
SCHEMBL26962799 0.81 ALDH1A1 (0.76) ALDH1A1MAPTSMN1; SMN2HPGDKDM4E
SCHEMBL3637836 0.81 HDAC3 (0.65) ALDH1A1MAPTSMN1; SMN2RAB9ANPC1
Ethyl Nicotinate SCHEMBL24853 0.81 L3MBTL1 (0.71) ALDH1A1MAPTKDM4ELMNAMAPK1
Ethyl Nicotinate SCHEMBL8164637 0.81 L3MBTL1 (0.71) ALDH1A1MAPTKDM4ELMNAMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220324899-A1 COMPOUNDS AND COMPOSITIONS FOR DIFFERENTIAL MODULATION OF NICOTINAMIDE ADENINE DINUCLEOTIDE METRO INTERNATIONAL BIOTECH, LLC 2022-10-13 US disclosed
EP-4013766-A1 COMPOUNDS AND COMPOSITIONS FOR DIFFERENTIAL MODULATION OF NICOTINAMIDE ADENINE DINUCLEOTIDE Metro International Biotech, LLC (US) 2022-06-22 EP disclosed
WO-2021030551-A1 COMPOUNDS AND COMPOSITIONS FOR DIFFERENTIAL MODULATION OF NICOTINAMIDE ADENINE DINUCLEOTIDE METRO INTERNATIONAL BIOTECH, LLC (US) 2021-02-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220324899-A1 COMPOUNDS AND COMPOSITIONS FOR DIFFERENTIAL MODULATION OF NICOTINAMIDE ADENINE DINUCLEOTIDE NQO1, NAMPT, NADK ALDH1A1 733/4885MAPT 2172/4885SMN1; SMN2 482/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.